Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER

INTRODUCTION: The HAWK and HARRIER studies evaluated the efficacy and safety of brolucizumab versus aflibercept in treatment-naïve eyes with neovascular age-related macular degeneration. Based on the study design, brolucizumab-treated eyes adjusted to a q8w regimen because the presence of disease ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Tadayoni, Ramin, Jaffe, Glenn J., Holz, Frank G., Schmidt-Erfurth, Ursula, Takahashi, Kanji, Cheung, Chui Ming Gemmy, Hariprasad, Seenu M., Gedif, Kinfemichael, Olsen, Rasmus, Best, Catherine, Igwe, Franklin, Kaiser, Peter K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287590/
https://www.ncbi.nlm.nih.gov/pubmed/37294524
http://dx.doi.org/10.1007/s40123-023-00735-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287590/
https://www.ncbi.nlm.nih.gov/pubmed/37294524
http://dx.doi.org/10.1007/s40123-023-00735-8

Ejemplares similares